CytomX Therapeutics (CTMX) Change in Accured Expenses (2014 - 2026)

CytomX Therapeutics has reported Change in Accured Expenses for 13 years, with the latest figure at -$3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 70.89% year-over-year to -$3.6 million; the trailing twelve-month figure through Mar 2026 stood at -$4.5 million (up 37.78% YoY), and the FY2025 full-year result was -$3.0 million, up 68.33% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$3.6 million, down from $486000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.0 million in Q3 2024, with the low at -$7.4 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged -$1.9 million across 5 years, with a median of -$1.7 million in 2024.
• The largest YoY upside for Change in Accured Expenses was 242.39% in 2023 against a maximum downside of 932.12% in 2023.
• CytomX Therapeutics' Change in Accured Expenses stood at -$3.9 million in 2022, then surged by 136.63% to $1.4 million in 2023, then sank by 490.03% to -$5.6 million in 2024, then jumped by 108.75% to $486000.0 in 2025, then tumbled by 840.53% to -$3.6 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.6 million (Q1 2026), $486000.0 (Q4 2025), and -$326000.0 (Q3 2025), per Business Quant data.